Efficacy of extended-release divalproex combined with condensed dialectical behavior therapy for individuals with borderline personality disorder
|
|
- Augustine Archibald McDonald
- 8 years ago
- Views:
Transcription
1 ANNALS OF CLINICAL PSYCHIATRY ANNALS OF CLINICAL PSYCHIATRY 2012;24(4): RESEARCH ARTICLE Efficacy of extended-release divalproex combined with condensed dialectical behavior therapy for individuals with borderline personality disorder Richelle Moen, PhD Department of Psychiatry University of Minnesota Medical School Minneapolis, MN, USA Mary Freitag, PsyD Integrative Psychological Services St. Paul, MN, USA Michael Miller, PsyD Susanne Lee, PhD Ann Romine, BA, RN Sue Song, MA Adit Adityanjee, MD S. Charles Schulz, MD Department of Psychiatry University of Minnesota Medical School Minneapolis, MN, USA BACKGROUND: Borderline personality disorder (BPD) is a significant psychiatric illness for which medication treatments are still being explored. The goal of this study was to assess divalproex extended release (ER) vs placebo for patients receiving dialectal behavior therapy (DBT). METHODS: Patients with BPD received 4 weeks of condensed DBT. Those with Symptom Checklist-90 (SCL-90) scores >150 after this treatment were then randomly and blindly assigned to placebo or divalproex ER for 12 weeks. Repeated measures analysis of variance utilizing last observation carried forward was used to assess the results. RESULTS: Seventeen participants completed the full assessment. Two patients had a significant decrease in SCL-90 in the first 4 weeks, leaving 15 patients for the medication phase of the trial. There were no significant differences between the participants assigned to divalproex ER compared with placebo. However, there was a significant improvement in both groups from baseline to endpoint (P =.001). CORRESPONDENCE S. Charles Schulz, MD Department of Psychiatry University of Minnesota Medical School F282/2A West 2450 Riverside Avenue Minneapolis, MN USA CONCLUSIONS: The response of 2 of 17 participants in the first 4 weeks prior to medication may point to a practice strategy in approaching outpatients with BPD. Although the patients had a decrease in symptoms during the study, there was no advantage observed for divalproex ER and DBT over placebo and DBT. KEYWORDS: borderline personality disorder, divalproex ER, dialectical behavior therapy scs@umn.edu AACP.com Annals of Clinical Psychiatry Vol. 24 No. 4 November
2 DIVALPROEX EXTENDED RELEASE FOR BORDERLINE PERSONALITY DISORDER INTRODUCTION Borderline personality disorder (BPD) is a common, chronic, and disabling disease that affects an estimated 1% to 2% of the general population 1 and has an 8% to 10% mortality rate. 2 The prevalence of BPD found in outpatient psychiatric clinics is 10%, although estimates suggest that as many as 20% of all psychiatric inpatient admissions meet full BPD criteria. BPD is twice as common in females vs males. Few patient groups require more mental health resources than BPD patients. BPD is known to be difficult to treat and treatment recommendations vary. 3 BPD is characterized by instability in interpersonal relationships, self-image, and affect; high emotional reactivity with difficulty returning to baseline; chronic feelings of emptiness; dissociative experiences; and marked impulsivity. Patients also experience impulsive risk-taking behavior, inappropriate/intense anger, self-injurious behavior, multiple suicide attempts, and brief psychotic episodes. Medication approaches to BPD have been tested in numerous studies over the last 25 years. Studies have examined a number of different compounds ranging from low doses of conventional 4,5 and atypical antipsychotic medications 6-9 to selective serotonin reuptake inhibitors. 10,11 Based on observations that BPD patients frequently have symptoms of impulsivity and/or aggression or that they may be comorbid with mood disorders such as bipolar II disorder, a number of studies have investigated divalproex as a treatment for BPD. 12,13 To date, Townsend et al 14 reported reduction in rating scale scores, but not statistically significant differences from placebo in the first controlled trial of divalproex. Frankenburg and Zanarini 12 examined divalproex in BPD patients who also met criteria for bipolar II disorder. They reported a significantly better outcome for the divalproex group on hostility scales. To refine the specificity of patients who may have the best response to divalproex, Hollander et al 15 studied the outcome of cluster B (impulsive and aggressive) behaviors in BPD patients, noting the superiority of divalproex in aggressive patients. Finally, to explore the potential of a new preparation of divalproex 1 with extended release (ER) Simeon et al 16 reported reduction in symptoms following administration of divalproex ER in an open-label trial. Of note, the design of previous divalproex studies tended to focus attention on the impulsive-aggressive BPD patients. Both divalproex and divalproex ER have shown significant potential for patients with BPD. Some of the recent review articles have critically assessed the efficacy data for both divalproex and divalproex ER However, next steps would be informative if they addressed issues of psychosocial treatment and placebo response. 20,21 For example, Schulz et al 22 noted a significant reduction in scores of BPD patients assigned to risperidone that was equal to the placebo response, thus indicating the importance of understanding psychosocial circumstances of patients in medication trials. Psychotherapeutic strategies are important for treating personality disorders. Dialectical behavior therapy (DBT) has been proven to be effective in BPD treatment in controlled studies. 23,24 Medication and psychosocial combinations have only recently begun to be explored with this population. In a 12-week, combined placebo-controlled trial of fluoxetine plus DBT vs placebo plus DBT, Simpson et al 25 found no significant differences in outcome measures between the 2 groups. On the other hand, Soler et al 21 found significant advantages for DBT plus olanzapine compared with DBT plus placebo in decreasing both depressive symptoms and impulsivity/aggressive behaviors in BPD patients. Linehan et al 20 found a more rapid reduction of irritability and aggression with DBT plus olanzapine than with DBT plus placebo, and both groups exhibited large and consistent reductions in aggression, depression, irritability, and self-injury. Therefore, a double-blind, placebo-controlled pilot trial was designed to address the usefulness of divalproex ER in BPD patients in the context of short-term DBT treatment. In order to address the frequently observed rapid response of some patients during the initial phase of the clinical trial, all participants received condensed DBT for 4 weeks, and only those with significant symptoms were randomly assigned to blinded divalproex ER or placebo while continuing DBT. Therefore, the study addressed the issue of rapid response of patients at study entry as well as usefulness of divalproex ER in BPD patients undergoing DBT treatment. METHODS Participants Recruitment of women and men age 21 to 55 who were disturbed by moodiness, distrustfulness, impulsivity, and painful and difficult relationships was accomplished primarily through newspaper and radio advertisements in the Minneapolis area. Local psychiatric clinics and mental health centers also were notified of the study, although 256 November 2012 Vol. 24 No. 4 Annals of Clinical Psychiatry
3 ANNALS OF CLINICAL PSYCHIATRY no clinical referrals were made. Participants were initially screened by telephone questionnaire using the 9 DSM-IV criteria for diagnosis of BPD. 3 Potential participants were excluded if they had a current or past history of bipolar disorder, schizophrenia, or major depression with psychotic features; were currently prescribed any psychotropic medication; or were acutely suicidal (ie, had a clear-cut and pressing intent to commit suicide in the near future). Although current diagnosis of major depression was an exclusion criterion, a history of major depression was allowed provided it had been 12 weeks since the last major depressive episode. No current alcohol or illicit substance dependency; a seizure disorder and/or anticonvulsant medications; or pregnancy were allowed. Women of childbearing potential were given a pregnancy test at the beginning of the study. Women who were pregnant, breastfeeding, planning to become pregnant, or not using a reliable form of contraception also were excluded. After the initial phone screen, patients were invited to participate in a face-to-face assessment screening interview. At that time, written informed consent, which was approved by the University of Minnesota institutional review board, was obtained. The following semi-structured diagnostic interview and symptom screening instruments were administered to each participant: 1) the Structured Clinical Interview for DSM-IV Axis I Disorders 26 ; 2) the Structured Clinical Interview for DSM-IV Axis II Disorder (SCID-II) 27 (along with past clinical records to screen for other mental illnesses); and 3) the Symptom Checklist-90 (SCL-90). 28 In order to be included in the study, all patients had to have a score of >150 on the SCL-90 indicating a high severity of symptoms, and meet 5 criteria on the SCID-II. In order to participate in the study, each potential research patient had to be medication free for 2 to 4 weeks. A 4-week medication-free period was required for patients on longacting depot medications. Study design In order to achieve the stated goals of the study, a 16-week, randomized, double-blind, placebo-controlled trial was designed. This controlled clinical trial consisted of a selection phase lasting 4 weeks and an experimental phase lasting 12 weeks. All participants were given the psychosocial intervention of condensed-dbt for 4 weeks and then reassessed. The SCL-90 was given for the second time on week 4. Those scoring >150 were considered nonresponders of condensed-dbt and were randomized to the double-blind (active drug vs placebo) phase. These nonresponders to the condensed-dbt were randomly and blindly assigned to receive continued condensed-dbt plus either divalproex ER or placebo on a 2:1 ratio. All participants continued 12 more weeks of the condensed-dbt (total 16-week program). The DBT skills training that was done in this study was based on the model of DBT for Adolescents, a condensed version of the skills, as modified by Alec Miller and Jill Rathus. This version allowed the participants to receive all 4 modules of skills in a 12-week period of time rather than the usual 26 weeks for adults. 29 Slight modifications of wording were needed to focus on adult behaviors vs adolescent and their parents references. Participants received the entire package of DBT, including all modes and functions of DBT, with weekly individual therapy sessions (45 to 50 minutes) incorporating the use of diary cards and behavioral chain analysis; skills training group (90 minutes); and telephone coaching calls (as-needed basis). The contract and commitment to this DBT program was the 16 weeks (not the 6 months of group or 1 year of individual therapy as prescribed by the formal DBT model of therapy). All therapists were intensively trained in DBT and participated in a mandatory weekly consultation group. After the screening and enrollment into the study, participants were assessed on the Hamilton Depression Rating Scale, 30 the Borderline Evaluation of Severity over Time (BEST), 31 and the Barratt Impulsivity Scale (BIS). 28,32 The BEST is a measure designed specifically to assess patients with BPD. It allows the patient to rate the degree of impairment or interference from each of the 9 BPD criteria over the past week; each item is rated on a 5-point scale, and scores can range from 12 to 72. The BIS is a 20-item selfreport measure with subscales measuring trait impulsivity. All participants received a physical examination, ECG, and laboratory testing (chemistry and hematology including comprehensive metabolic panel [renal and hepatic], complete blood count, thyroid-stimulating hormone, and urinalysis) to ascertain health status. Any medical illness thought to interfere with the study was cause for exclusion. Laboratory testing was performed at the same time as the divalproex ER blood level at weeks 3, 6, 11, and 13 weeks after starting the study drug. The time of the last divalproex ER dose was documented, and divalproex ER levels were drawn approximately 24 hours after the last dose to assess relevant trough levels. All raters were kept blind of the serum divalproex level results. Only one study physician (A.A.), who did not participate in the ratings, was privy to the results of serum divalproex levels. AACP.com Annals of Clinical Psychiatry Vol. 24 No. 4 November
4 DIVALPROEX EXTENDED RELEASE FOR BORDERLINE PERSONALITY DISORDER TABLE 1 Demographic characteristics of divalproex ER, placebo, and non-randomized groups Divalproex ER (n = 10) Placebo (n = 5) Age range 23 to to 51 Mean age Sex (F, M) 9, 1 3, 2 Race White 9 3 Black 0 1 Hispanic 0 1 Mixed 1 0 Mean high dose (range) Completed 16-week trial 1,600 (1,000 to 2,000) 1,583 (1,500 to 2,000) n = 6 n = 3 Mean weight gain (lbs) ER: extended release. To study the possibility of medication side effects, all physical and psychiatric symptoms were recorded. Patients weight and height were measured at entry to double-blind study (to calculate body mass index) and at completion of the trial. Divalproex ER dosing. Blood samples were obtained to measure blood concentration of divalproex ER at weeks 4, 8, and 16. A study physician then adjusted the dose to maintain the medication at the therapeutic range. The study physician changed the dosing the study medicine and placebo at pre-determined dose-escalation steps so as not to reveal medication assignment. Data analysis Statistical analysis of data was conducted using SPSS v.16 (Chicago, IL, USA). Chi-square analyses and oneway analysis of variance (ANOVA) were used to compare demographic characteristics between the 2 groups. Repeated measures ANOVA using last observation carried forward (LOCF) data was used to test group differences in rate of change over time on the SCL-90 total score, the BIS- Motor Score, and the BEST total score. Non-parametric test (Kruskal-Wallis test) was applied to explore group differences in the SCL-90 total score, the BIS-Motor Score, and the BEST total score at each timepoint. Non-parametric test was used for the exploratory analysis due to small sample size and high variability in scores. All statistical tests were 2-tailed with a significance of.05. RESULTS Twenty-nine participants completed the telephone interview after volunteering to be in the study and signed informed consent for the diagnostic and symptom rating assessment for study entry. Nine were screen failures. Of the 20 participants who were eligible to continue in the trial, 3 withdrew during the 4-week period of DBT before randomization in the medication trial, leaving 17 patients to go forward with the trial. Two of the participants SCL-90 scores were too low to meet criteria for randomization, but continued DBT. Fifteen participants were randomized to either divalproex ER or placebo (TABLE 1). In the divalproex ER group, 6 out of 10 patients completed the study and 3 out of 5 assigned to placebo remained in the study until completion. Assessment of participation in the condensed DBT section of the study revealed that only 1 individual missed >2 of the 16 sessions. TABLE 2 summarizes the means and standard deviations on the SCL-90 total score; BIS-Motor Score; and the BEST parts A+B (Negative Thoughts, Feelings, and Behaviors) score. According to the repeated measures ANOVA on the group difference in outcomes measured over time, there was no significant Time Group interaction (slope) as assessed by the SCL-90 total score [F(8,56) = 1.09; P =.38] or BIS-Motor Score [F(6,39) = 0.21; P =.97]. Although no significant group differences were found in the slopes, there was a significant time effect on the SCL-90 overall score, which indicated that the 2 groups showed improvement over time [F(4,56) = 5.36; P <.001]. The statistically significant improvement of all the participants in the study are consistent with the current findings of BPD patients having better outcomes 33 (TABLE 2). Because of small sample size and high variability in scores, we applied nonparametric tests (Kruskal-Wallis Test) to compare the 2 groups at each timepoint. There was no significant group difference in the SCL-90 overall score (screening χ 2 [2] = 4.42, P =.11; randomization χ 2 [2] = 5.25, P =.07; week 4 χ 2 [2] = 4.44, P =.11; week 8 χ 2 [2] = 3.98, P =.14; week 12 χ 2 [2] 3.70, P =.16) or the BIS-Motor Score (randomization χ 2 [2] = 1.87, P =.39; week 4 χ 2 [2] = 1.72, P =.42; week 8 χ 2 [2] = 1.90, P =.39; week 12 χ 2 [2] = 2.65, P =.27). Several side effects were reported during the study. Patients receiving divalproex ER during the study noted weight gain, sedation, confusion, increased appetite, yawning, vivid dreams, tremor, edema, and tinnitus. Patients on 258 November 2012 Vol. 24 No. 4 Annals of Clinical Psychiatry
5 ANNALS OF CLINICAL PSYCHIATRY placebo also reported weight gain (although mean measures of weight declined), insomnia, and headache. Reasons for early withdrawal for the 4 divalproex ER participants were: increased liver enzymes, stopped attending and did not return calls, assessed as potential risk to others, and did not like group therapy. For the placebo group, the reasons for early withdrawal were complaint of no change and a statement of stopping for personal reasons. DISCUSSION Our primary goal with this study was to examine the safety and efficacy of divalproex ER while addressing the impact of the placebo effect and controlled psychosocial intervention. One of the most interesting findings within this study was the effectiveness of the 4-week run-in of condensed DBT, which allowed us to separate out potential placebo, and/or early responders who benefited from treatment without medications. Almost 12% (2 of 17) of our study patients improved with therapy alone. Our research design is unique in how it mirrors psychology practice (therapists and psychologists) in that the patient s response to therapy determines the need for a referral for medication. All patients improved over time, even though there were no significant differences between the 2 randomized groups. These findings were consistent with earlier findings by Simpson et al, 25 who reported that combined DBT plus fluoxetine did not have an advantage over DBT plus placebo. On the other hand, our results are unlike recent studies by Linehan et al 20 and Soler et al, 21 in which DBT plus olanzapine was found to be significantly superior to DBT plus placebo for improving mood/anxiety symptoms and impulsive behavior. Although the patients assigned to divalproex ER had a reduction in symptoms over the course of the study, similar to results seen in earlier studies, the change was not greater than that observed in the placebo group. Limitations of the study This study has several methodologic limitations. First, although intended as a pilot study of a new medication, the small sample size limited our statistical power to investigate significant treatment group differences as well as our ability to generalize from our sample. Regarding the issue of whether a larger sample could have led to a TABLE 2 Means and standard deviations on SCL- 90 total score, BIS-Motor Score, and BEST Parts A+B (Negative Thoughts, Feelings, and Behaviors) score SCL-90 Total Score Divalproex ER Placebo M SD M SD Baseline Randomization Week Week Week BIS-Motor Score Randomization Week Week Week BEST A+B Score Randomization Week Week Week BEST: Borderline Evaluation of Severity over Time; BIS: Barratt Impulsivity Scale; ER: extended release; M: mean; SCL-90: Symptoms Checklist-90; SD: standard deviation. significant difference between groups, it is of note that the placebo group had numerically greater response. In addition, only 6 patients in the divalproex ER- and 3 patients in the placebo-treated group completed the entire 12-week medication trial (a 60% completion rate). Because of the LOCF analysis, data of all participants were included in the report of the statistical outcome. Because BPD is not a homogeneous population, studies are needed to increase our understanding of subcategories of BPD patients, such as those who may benefit from briefer vs longer interventions or those with symptoms that may be more responsive to divalproex ER. 15 For example, a recent meta-analysis by Ingenhoven et al 34 showed a targeted effect of divalproex for aggression and agitation. This patient group was not selected for specific subtypes of behaviors. It should be noted that there was no difference between divalproex ER and placebo on the BIS. Moreover, no life-event measure or scale was used to ascertain presence or absence and putative severity of a recent life crisis in the lives of study patients. The self- AACP.com Annals of Clinical Psychiatry Vol. 24 No. 4 November
6 DIVALPROEX EXTENDED RELEASE FOR BORDERLINE PERSONALITY DISORDER referred research volunteers may have sought clinical help through the study participation following a life crisis leading to their recruitment in the study. Also, there may be some concern about the mean age of the research participants (mid-30s) and the need to study less persistently ill patients. Lastly, it should be noted that the psychosocial treatment condensed DBT was chosen to match the length of time of the trial. However, this treatment has not been validated for adult patients with DBT. Therefore, a replication of this approach is warranted. CONCLUSIONS In summary, divalproex has shown efficacy in some studies and the ER formulation was tested in this pilot trial. In addition, other issues of concern in BPD trials were incorporated into the study, including the treatment with condensed DBT during the medication trial and the exclusion of the rapidly responding patients prior to randomization. DISCLOSURES: Dr. Schulz receives grant or research support from AstraZeneca, Myriad RBM, and Otsuka and is a consultant to Eli Lilly and Company and Genetech. Drs. Moen, Freitag, Miller, Lee, and Adityanjee and Ms. Romine and Ms. Song report no financial relationships with any company whose products are mentioned in this article or with manufacturers of competing products. ACKNOWLEDGEMENTS: This study was sponsored by a research grant from Abbott Pharmaceuticals to the principal investigator, S. Charles Schulz, MD. REFERENCES 1. Torgersen S, Kringlen E, Cramer V. The prevalence of personality disorders in a community sample. Arch Gen Psychiatry. 2001;58: Pompili M, Girardi P, Ruberto A, et al. Suicide in borderline personality disorder: a meta-analysis. Nord J Psychiatry. 2005;59: Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association. Am J Psychiatry. 2001;158(10 suppl): Goldberg SC, Schulz SC, Schulz PM, et al. Borderline and schizotypal personality disorders treated with lowdose thiothixene vs placebo. Arch Gen Psychiatry. 1986; 43: Soloff PH, George A, Nathan RS, et al. Progress in pharmacotherapy of borderline disorders. A doubleblind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry. 1986;43: Nickel MK, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006;163: Schulz SC, Camlin KL, Berry SA, et al. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry. 1999;46: Schulz SC, Zanarini MC, Bateman A, et al. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebocontrolled study. Br J Psychiatry. 2008;193: Adityanjee, Romine A, Brown E, et al. Quetiapine in patients with borderline personality disorder: an openlabel trial. Ann Clin Psychiatry. 2008;20: Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry. 1997;54: Markovitz PJ, Calabrese JR, Schulz SC, et al. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry. 1991;148: Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 2002;63: Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry. 2001;62: Townsend MH, Cambre KM, Barbee JG. Treatment of borderline personality disorder with mood instability with divalproex sodium: series of ten cases. J Clin Psychopharmacol. 2001;21: Hollander E, Swann AC, Coccaro EF, et al. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry. 2005;162: Simeon D, Baker B, Chaplin W, et al. An openlabel trial of divalproex extended-release in the treatment of borderline personality disorder. CNS Spectr. 2007;12: Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of pharmacotherapies for borderline personality disorder. CNS Drugs. 2008;22: Herpertz SC, Zanarini M, Schulz CS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J Biol Psychiatry. 2007;8: Lieb K, Völlm B, Rücker G, et al. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry. 2010; 196: Linehan MM, McDavid JD, Brown MZ, et al. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008;69: Soler J, Pascual JC, Campins J, et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005;162: Schulz SC, Camlin KL, Berry SA, et al. A doubleblind, placebo-controlled study of risperidone for borderline personality disorder: a preliminary report. Presented at: 37th ACNP Annual Meeting; December, 14-18, 1998; San Juan, PR. 23. Linehan MM, Comtois KA, Murray AM, et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry. 2006;63: Robins CJ, Chapman AL. Dialectical behavior therapy: current status, recent developments, and future directions. J Pers Disord. 2004;18: Simpson EB, Yen S, Costello E, et al. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65: First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders. New York, NY: New York State Psychiatric Institute, Biometrics Research Department; First MB, Spitzer RL, Gibbon M, et al. The Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II). Part II: multi-site test-retest reliability study. J Pers Disord. 1995;9: Derogatis RL. The SCL-R-90 manual I: scoring, administration and procedures for the SCL-90. Baltimore, MD: Clinical Psychometric Research; Miller AL, Rathus JH, Linehan MM, et al. Dialectical behavior therapy adapted for suicidal adolescents. Journal of Practical Psychiatry and Behavioral Health. 1997;3: Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23: Pfohl B, Blum N, St John D, et al. Reliability and validity of the Borderline Evaluation of Severity Over Time (BEST): a self-rated scale to measure severity and change in persons with borderline personality disorder. J Pers Disord. 2009;23: Barratt E, Patton JH. Impulsivity: cognitive, behavioral and psychophysiological correlates. In: Zuckerman M, ed. The biological basis of sensation seeking, impulsivity, and anxiety. Hillsdale, NJ: Lawrence Earlbaum Associates; 1983: Gunderson JG, Stout RL, McGlashan TH, et al. Ten-year course of borderline personality disorder: psychopathology and function from the Collaborative Longitudinal Personality Disorders study. Arch Gen Psychiatry. 2011;68: Ingenhoven T, Lafay P, Rinne T, et al. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry. 2010;71: November 2012 Vol. 24 No. 4 Annals of Clinical Psychiatry
HOW TO THINK ABOUT MEDICATIONS IN THE TREATMENT OF BPD
HOW TO THINK ABOUT MEDICATIONS IN THE TREATMENT OF BPD Kenneth R Silk, MD Professor Emeritus of Psychiatry University of Michigan Health System Ann Arbor, MI 48109-2700 ksilk@umich.edu DISCLOSURES l I
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder,
More informationTREATING ASPD IN THE COMMUNITY: FURTHERING THE PD OFFENDER STRATEGY. Jessica Yakeley Portman Clinic Tavistock and Portman NHS Foundation Trust
TREATING ASPD IN THE COMMUNITY: FURTHERING THE PD OFFENDER STRATEGY Jessica Yakeley Portman Clinic Tavistock and Portman NHS Foundation Trust Treating the untreatable? Lack of evidence base for ASPD Only
More informationContents of This Packet
Contents of This Packet 1) Overview letter 2) Dialectical Behavior Therapy (DBT) Clinic flyer 3) Diagnostic criteria for borderline personality disorder 4) Guidelines and agreements for participating in
More informationBipolar Disorder. Mania is the word that describes the activated phase of bipolar disorder. The symptoms of mania may include:
Bipolar Disorder What is bipolar disorder? Bipolar disorder, or manic depression, is a medical illness that causes extreme shifts in mood, energy, and functioning. These changes may be subtle or dramatic
More informationDEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource
E-Resource March, 2015 DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource Depression affects approximately 20% of the general population
More informationThe NICE Borderline Personality Disorder guideline the evidence
The NICE Borderline Personality Disorder guideline the evidence Bologna, Italy, 11 th June 2013 Professor Tim Kendall Director of National Collaborating Centre for Mental Health, Royal College of Psychiatrists
More informationAntipsychotic drugs are the cornerstone of treatment
Article Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic T. Scott Stroup, M.D.,
More informationComorbid Conditions in Autism Spectrum Illness. David Ermer MD June 13, 2014
Comorbid Conditions in Autism Spectrum Illness David Ermer MD June 13, 2014 Overview Diagnosing comorbidities in autism spectrum illnesses Treatment issues specific to autism spectrum illnesses Treatment
More informationTHE DEPRESSION RESEARCH CLINIC Department of Psychiatry and Behavioral Sciences Stanford University, School of Medicine
THE DEPRESSION RESEARCH CLINIC Department of Psychiatry and Behavioral Sciences Stanford University, School of Medicine Volume 1, Issue 1 August 2007 The Depression Research Clinic at Stanford University
More informationMedical marijuana for pain and anxiety: A primer for methadone physicians. Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015
Medical marijuana for pain and anxiety: A primer for methadone physicians Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015 Conflict of interest statement No conflict of interest to
More informationThe Efficacy of Pharmacotherapy for Borderline Personality Disorder: A Review of the Available Randomized Controlled Trials
The Efficacy of Pharmacotherapy for Borderline Personality Disorder: A Review of the Available Randomized Controlled Trials Dimitry Francois, MD; Steven D. Roth, MD, JD; and Daisy Klingman, MD ABSTRACT
More informationTREATING MAJOR DEPRESSIVE DISORDER
TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.
More informationBorderline Personality Disorder NEA-BPD Meet and Greet New York, NY October 21, 2011
Borderline Personality Disorder NEA-BPD Meet and Greet New York, NY October 21, 2011 John M. Oldham, M.D. Senior Vice President and Chief of Staff The Menninger Clinic; Professor and Executive Vice Chair
More informationClozapine in borderline personality disorder: A review of the evidence
ANNALS OF CLINICAL PSYCHIATRY ANNALS OF CLINICAL PSYCHIATRY 2014;26(2):139-144 REVIEW ARTICLE Clozapine in borderline personality disorder: A review of the evidence Anand Beri, MRCPsych South London and
More informationA One Year Study Of Adolescent Males With Aggression and Problems Of Conduct and Personality: A comparison of MDT and DBT
A One Year Study Of Adolescent Males With Aggression and Problems Of Conduct and Personality: A comparison of MDT and DBT Jack A. Apsche, Christopher K. Bass and Marsha-Ann Houston Abstract This study
More informationPersonality Disorders (PD) Summary (print version)
Personality Disorders (PD) Summary (print version) 1/ Definition A Personality Disorder is an abnormal, extreme and persistent variation from the normal (statistical) range of one or more personality attributes
More informationFor personal use only
AT For mass reproduction, content licensing and permissions contact Dowden Health Media. BE Copyright Dowden Health Media For personal use only Removing immediate access to lethal means may give the patient
More informationWinter 2013, SW 713-001, Thursdays 2:00 5:00 p.m., Room B684 SSWB
1 Winter 2013, SW 713-001, Thursdays 2:00 5:00 p.m., Room B684 SSWB DIALECTICAL BEHAVIOR THERAPY SOCIAL WORK PRACTICE IN MENTAL HEALTH EMPERICALLY SUPPORTED TREATMENT FOR INDIVIDUALS WITH SEVERE EMOTION
More informationADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines - 2015
The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least
More informationConjoint Professor Brian Draper
Chronic Serious Mental Illness and Dementia Optimising Quality Care Psychiatry Conjoint Professor Brian Draper Academic Dept. for Old Age Psychiatry, Prince of Wales Hospital, Randwick Cognitive Course
More informationDSM 5 AND DISRUPTIVE MOOD DYSREGULATION DISORDER Gail Fernandez, M.D.
DSM 5 AND DISRUPTIVE MOOD DYSREGULATION DISORDER Gail Fernandez, M.D. GOALS Learn DSM 5 criteria for DMDD Understand the theoretical background of DMDD Discuss background, pathophysiology and treatment
More informationBorderline Personality Disorder
Borderline Personality Disorder Borderline Personality Disorder Formerly called latent schizophrenia Added to DSM III (1980) as BPD most commonly diagnosed in females (75%) 70-75% have a history of at
More informationMarsha M. Linehan, Ph.D.; Joshua D. McDavid, M.D., M.P.H.; Milton Z. Brown, Ph.D.; Jennifer H. R. Sayrs, Ph.D.; and Robert J. Gallop, Ph.D.
Olanzapine Plus Dialectical Behavior Therapy for Women With High Irritability Who Meet Criteria for Borderline Personality Disorder: A Double-Blind, Placebo-Controlled Pilot Study Marsha M. Linehan, Ph.D.;
More informationMental Health Needs Assessment Personality Disorder Prevalence and models of care
Mental Health Needs Assessment Personality Disorder Prevalence and models of care Introduction and definitions Personality disorders are a complex group of conditions identified through how an individual
More informationRecent Research On Emotionally Unstable (Borderline) Personality Disorder
Recent Research On Emotionally Unstable (Borderline) Personality Disorder Internet Mental Health: Editor s Choice Can J Psychiatry. 2005 Jul;50(8):435-41. Comment in: Can J Psychiatry. 2005 Jul;50(8):433-4.
More informationBorderline Personality Disorder and Treatment Options
Borderline Personality Disorder and Treatment Options MELISSA BUDZINSKI, LCSW VICE PRESIDENT, CLINICAL SERVICES 2014 Horizon Mental Health Management, LLC. All rights reserved. Objectives Define Borderline
More informationBorderline Personality Disorder
Borderline Personality Disorder What is Borderline Personality Disorder? Borderline Personality Disorder (BPD) is a most misunderstood, serious mental illness characterized by pervasive instability in
More informationDEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE
1 DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE ASSESSMENT/PROBLEM RECOGNITION 1. Did the staff and physician seek and document risk factors for depression and any history of depression? 2. Did staff
More informationPathological Gambling and Age: Differences in personality, psychopathology, and response to treatment variables
Addictive Behaviors 30 (2005) 383 388 Short communication Pathological Gambling and Age: Differences in personality, psychopathology, and response to treatment variables A. González-Ibáñez a, *, M. Mora
More informationKENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE
KENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE 201 KAR 9:260. Professional standards for prescribing and dispensing controlled substances.
More informationDoes Non-Suicidal Self-injury Mean Developing Borderline Personality Disorder? Dr Paul Wilkinson University of Cambridge
Does Non-Suicidal Self-injury Mean Developing Borderline Personality Disorder? Dr Paul Wilkinson University of Cambridge If I see a patient who cuts themself, I just assume they have borderline personality
More informationAxis II comorbidity of borderline personality disorder: description of 6-year course and prediction to time-to-remission
Acta Psychiatr Scand 2004: 110: 416 420 Printed in UK. All rights reserved DOI: 10.1111/j.1600-0447.2004.00362.x Copyright Ó Blackwell Munksgaard 2004 ACTA PSYCHIATRICA SCANDINAVICA Axis II comorbidity
More informationCARE MANAGEMENT FOR LATE LIFE DEPRESSION IN URBAN CHINESE PRIMARY CARE CLINICS
CARE MANAGEMENT FOR LATE LIFE DEPRESSION IN URBAN CHINESE PRIMARY CARE CLINICS Dept of Public Health Sciences February 6, 2015 Yeates Conwell, MD Dept of Psychiatry, University of Rochester Shulin Chen,
More informationEmergency Room Treatment of Psychosis
OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different
More informationBorderline personality disorder
Borderline personality disorder Treatment and management Issued: January 2009 NICE clinical guideline 78 guidance.nice.org.uk/cg78 NICE 2009 Contents Introduction... 3 Person-centred care... 5 Key priorities
More informationAffective Instability in Borderline Personality Disorder. Brad Reich, MD McLean Hospital
Affective Instability in Borderline Personality Disorder Brad Reich, MD McLean Hospital Characteristics of Affective Instability Rapidly shifting between different emotional states, usually involving a
More informationSYNOPSIS. Risperidone: Clinical Study Report CR003274
SYNOPSIS Protocol No: CR003274 Title of Study: An Open-Label, Long-Term Trial of Risperidone Long-Acting Microspheres in the Treatment of Subjects Diagnosed with Schizophrenia Coordinating Investigator:
More informationClinical Practice Guidelines: Attention Deficit/Hyperactivity Disorder
Clinical Practice Guidelines: Attention Deficit/Hyperactivity Disorder AACAP Official Action: OUTLINE OF PRACTICE PARAMETERS FOR THE ASSESSMENT AND TREATMENT OF CHILDREN, ADOLESCENTS, AND ADULTS WITH ADHD
More informationThis continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC.
This continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC. Indiana University School of Medicine and CME Outfitters, LLC, gratefully acknowledge
More informationWhat happens to depressed adolescents? A beyondblue funded 3 9 year follow up study
What happens to depressed adolescents? A beyondblue funded 3 9 year follow up study Amanda Dudley, Bruce Tonge, Sarah Ford, Glenn Melvin, & Michael Gordon Centre for Developmental Psychiatry & Psychology
More informationTreatment Interventions for Suicide Prevention. Kate Comtois, PhD, MPH University of Washington
Treatment Interventions for Suicide Prevention Kate Comtois, PhD, MPH University of Washington Suicide prevention has many forms Treating Depression Gatekeeper Training Public health or injury prevention
More informationTeacher-reported Dissociation in Young Children Whose Mothers Have Borderline Personality Disorder: A Problem with Self-Development
Teacher-reported Dissociation in Young Children Whose Mothers Have Borderline Personality Disorder: A Problem with Self-Development Amineh Abbas, Christopher D. Watkins, Jennifer M. Strimpfel, Christina
More informationOptum By United Behavioral Health. 2015 Florida Medicaid Managed Medical Assistance (MMA) Level of Care Guidelines
Optum By United Behavioral Health 2015 Florida Medicaid Managed Medical Assistance (MMA) Level of Care Guidelines Therapeutic group care services are community-based, psychiatric residential treatment
More informationDepression Assessment & Treatment
Depressive Symptoms? Administer depression screening tool: PSC Depression Assessment & Treatment Yes Positive screen Safety Screen (see Appendix): Administer every visit Neglect/Abuse? Thoughts of hurting
More informationManaging depression after stroke. Presented by Maree Hackett
Managing depression after stroke Presented by Maree Hackett After stroke Physical changes We can see these Depression Emotionalism Anxiety Confusion Communication problems What is depression? Category
More informationDiagnosis: Appropriate diagnosis is made according to diagnostic criteria in the current Diagnostic and Statistical Manual of Mental Disorders.
Page 1 of 6 Approved: Mary Engrav, MD Date: 05/27/2015 Description: Eating disorders are illnesses having to do with disturbances in eating behaviors, especially the consuming of food in inappropriate
More informationPsychopharmacotherapy for Children and Adolescents
TREATMENT GUIDELINES Psychopharmacotherapy for Children and Adolescents Guideline 7 Psychopharmacotherapy for Children and Adolescents Description There are few controlled trials to guide practitioners
More informationAlgorithm for Initiating Antidepressant Therapy in Depression
Algorithm for Initiating Antidepressant Therapy in Depression Refer for psychotherapy if patient preference or add cognitive behavioural office skills to antidepressant medication Moderate to Severe depression
More informationImproving the Recognition and Treatment of Bipolar Depression
Handout for the Neuroscience Education Institute (NEI) online activity: Improving the Recognition and Treatment of Bipolar Depression Learning Objectives Apply evidence-based tools that aid in differentiating
More informationA Hospital Based Residential DBT Program for Adolescent Girls with Borderline Personality Disorder
A Hospital Based Residential DBT Program for Adolescent Girls with Borderline Personality Disorder BLAISE AGUIRRE, MD MEDICAL DIRECTOR 3EAST ADOLESCENT DBT UNIT MCLEAN HOSPITAL Objectives To describe the
More informationTHE EVALUATION OF PSYCHOANALYTICALLY INFORMED TREATMENT PROGRAMS FOR SEVERE PERSONALITY DISORDER: A CONTROLLED STUDY Marco Chiesa & Peter Fonagy
THE EVALUATION OF PSYCHOANALYTICALLY INFORMED TREATMENT PROGRAMS FOR SEVERE PERSONALITY DISORDER: A CONTROLLED STUDY Marco Chiesa & Peter Fonagy Aims Summary The aim of this study was to compare the effectiveness
More informationAntipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease
Antipsychotic Medications and the Risk of Diabetes and Cardiovascular Disease Professional Tool #1: Screening and Monitoring in a High-Risk Population: Questions and Answers Overview of Cardiometabolic
More informationClinical Practice Guideline for the Management of Borderline Personality Disorder
Clinical Practice Guideline for the Management of Borderline Personality Disorder Clinical Practice Guideline for the Management of Borderline Personality Disorder 2012 Printed document Commonwealth of
More informationGood Practice, Evidence Base and Implementation Issues: Personality Disorder. Prof Anthony W Bateman SMI Stake Holder Event
Good Practice, Evidence Base and Implementation Issues: Personality Disorder Prof Anthony W Bateman SMI Stake Holder Event Treatment for Borderline Personality Disorder A range of structured treatment
More informationLisa Davies Consultant Forensic Psychologist Malta, October 2012
Lisa Davies Consultant Forensic Psychologist Malta, October 2012 What is Borderline Personality Disorder How to treat BPD effectively Pink Elephants Principles of Dialectical Behaviour Therapy BPD is:
More informationClient Information Leaflet
The Dialectical Behaviour Therapy Endeavour Programme Creating a life worth living Client Information Leaflet HSE South - North Lee Adult Mental Health Service Dialectical Behaviour Therapy Programme July
More informationUsing Dialectical Behavioural Therapy with Eating Disorders. Dr Caroline Reynolds Consultant Psychiatrist Richardson Eating Disorder Service
Using Dialectical Behavioural Therapy with Eating Disorders Dr Caroline Reynolds Consultant Psychiatrist Richardson Eating Disorder Service Contents What is dialectical behavioural therapy (DBT)? How has
More informationBIPOLAR DISORDER IN PRIMARY CARE
E-Resource January, 2014 BIPOLAR DISORDER IN PRIMARY CARE Mood Disorder Questionnaire Common Comorbidities Evaluation of Patients with BPD Management of BPD in Primary Care Patient resource Patients with
More informationRobert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy
Robert Okwemba, BSPHS, Pharm.D. 2015 Philadelphia College of Pharmacy Judith Long, MD,RWJCS Perelman School of Medicine Philadelphia Veteran Affairs Medical Center Background Objective Overview Methods
More informationNew York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery
New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery USING THE 48 HOUR OBSERVATION BED USING THE 48 HOUR OBSERVATION BED Detoxification
More informationPersonality disorders constitute a major group in the. Borderline personality disorder. Review Synthèse. Causes: biological, psychological and social
Review Synthèse Borderline personality disorder Joel Paris DOI:10.1503/cmaj.045281 Abstract BORDERLINE PERSONALITY DISORDER is a chronic psychiatric disorder characterized by marked impulsivity, instability
More informationBorderline Personality: Traits and Disorder
Journal of Abnormal Psychology Copyright 2000 by the American Psychological Association, Inc. 2000, Vol. 109, No. 4, 733-737 0021-843X/00/$5.00 DOI: 10.1037//0021-843X.109.4.733 Borderline Personality:
More informationMajor Depressive Disorders Questions submitted for consideration by workshop participants
Major Depressive Disorders Questions submitted for consideration by workshop participants Prioritizing Comparative Effectiveness Research Questions: PCORI Stakeholder Workshops June 9, 2015 Patient-Centered
More informationPsychology Externship Program
Psychology Externship Program The Washington VA Medical Center (VAMC) is a state-of-the-art facility located in Washington, D.C., N.W., and is accredited by the Joint Commission on the Accreditation of
More informationTreatment of Prescription Opioid Dependence
Treatment of Prescription Opioid Dependence Roger D. Weiss, MD Chief, Division of Alcohol and Drug Abuse McLean Hospital, Belmont, MA Professor of Psychiatry, Harvard Medical School, Boston, MA Prescription
More informationDepression Remission at Six Months Specifications 2014 (Follow-up Visits for 07/01/2012 to 06/30/2013 Index Contact Dates)
Description Methodology Rationale Measurement Period A measure of the percentage of adults patients who have reached remission at six months (+/- 30 days) after being identified as having an initial PHQ-9
More informationA Manic Episode is defined by a distinct period during which there is an abnormally and persistently elevated, expansive, or irritable mood.
Bipolar disorder Bipolar (manic-depressive illness) is a recurrent mode disorder. The patient may feel stable at baseline level but experience recurrent shifts to an emotional high (mania or hypomania)
More informationCOMMUNITY MENTAL HEALTH RESOURCES
COMMUNITY MENTAL HEALTH RESOURCES (Adult Mental Health Initiative) Ramsey & Washington Information gathered by: MN. State Advisory Council on Mental Health 17-25 Year Old Committee Mental Health Services
More informationIrritability and DSM-5 Disruptive Mood Dysregulation Disorder (DMDD): Correlates, predictors, and outcome in children
Irritability and DSM-5 Disruptive Mood Dysregulation Disorder (DMDD): Correlates, predictors, and outcome in children Ellen Leibenluft, M.D. Chief, Section on Bipolar Spectrum Disorders National Institute
More informationRunning Head: INTERNET USE IN A COLLEGE SAMPLE. TITLE: Internet Use and Associated Risks in a College Sample
Running Head: INTERNET USE IN A COLLEGE SAMPLE TITLE: Internet Use and Associated Risks in a College Sample AUTHORS: Katherine Derbyshire, B.S. Jon Grant, J.D., M.D., M.P.H. Katherine Lust, Ph.D., M.P.H.
More informationWhat is a personality disorder?
What is a personality disorder? What is a personality disorder? Everyone has personality traits that characterise them. These are the usual ways that a person thinks and behaves, which make each of us
More informationSCREENING FOR CO-OCCURRING DISORDERS USING THE MODIFIED MINI SCREEN (MMS) USER S GUIDE. (Rev. 6/05)
SCREENING FOR CO-OCCURRING DISORDERS USING THE MODIFIED MINI SCREEN (MMS) USER S GUIDE (Rev. 6/05) ACKNOWLEDGEMENTS This user guide was developed by the NYS Practice Improvement Collaborative (PIC) under
More informationTITLE: Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines
TITLE: Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines DATE: 01 December 2009 CONTEXT AND POLICY ISSUES: Post-traumatic stress disorder
More informationDialectical Behaviour Therapy (DBT) for Borderline Personality Disorder
Dialectical Behaviour Therapy (DBT) for Borderline Personality Disorder Dr. Kathy Fitch, Psychiatrist Janice Wingrave,, RPN, Clinical Supervisor Janice Wingrave,, RPN Clinical supervisor to comprehensive
More informationPSYCHOSOCIAL FUNCTIONING IN PATIENTS WITH PERSONALITY DISORDERS: A REVIEW OF THE EVIDENCE-BASED RESEARCH STUDIES LITERATURE
PSYCHOSOCIAL FUNCTIONING IN PATIENTS WITH PERSONALITY DISORDERS: A REVIEW OF THE EVIDENCE-BASED RESEARCH STUDIES LITERATURE Wendy Dávila Wood, Aizpea Boyra and José Guimón onpguugj@ehu.es SUMMARY Evidence
More informationHow to Recognize Depression and Its Related Mood and Emotional Disorders
How to Recognize Depression and Its Related Mood and Emotional Disorders Dr. David H. Brendel Depression s Devastating Toll on the Individual Reduces or eliminates pleasure and jo Compromises and destroys
More informationElizabeth A. Crocco, MD Assistant Clinical Professor Chief, Division of Geriatric Psychiatry Department of Psychiatry and Behavioral Sciences Miller
Elizabeth A. Crocco, MD Assistant Clinical Professor Chief, Division of Geriatric Psychiatry Department of Psychiatry and Behavioral Sciences Miller School of Medicine/University of Miami Question 1 You
More informationNot All Clinical Trials Are Created Equal Understanding the Different Phases
Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact
More informationDepression Flow Chart
Depression Flow Chart SCREEN FOR DEPRESSION ANNUALLY Assess for depression annually with the PHQ-9. Maintain a high index of suspicion in high risk older adults. Consider suicide risk and contributing
More informationCourse outline. Acupuncture in Mental Health. History of Acupuncture and Psychiatry in HK
Course outline Acupuncture in Mental Health Simon HUI Senior Physiotherapist Kwai Chung Hospital Updated evidences for using acupuncture in Mental health A literature review Local experience for using
More informationInformed Consent for Research in Borderline Personality Disorder
Informed Consent for Research in Borderline Personality Disorder Rachel E. Dew MD Post-doctoral Fellow, Center for Spirituality, Theology, and Health, Duke University Medical Center, Durham, NC Adjunct
More informationTreatment Trials For People With Borderline Personality Disorders
ANNALS OF CLINICAL PSYCHIATRY 2010;22(2):75-83 REVIEW ARTICLE Methodological considerations for treatment trials for persons with borderline personality disorder Mary C. Zanarini, EdD Barbara Stanley,
More informationAppendix B NMMCP Covered Services and Exceptions
Acute Inpatient Hospitalization MH - Adult Definition An Acute Inpatient program is designed to provide medically necessary, intensive assessment, psychiatric treatment and support to individuals with
More informationFrequent headache is defined as headaches 15 days/month and daily. Course of Frequent/Daily Headache in the General Population and in Medical Practice
DISEASE STATE REVIEW Course of Frequent/Daily Headache in the General Population and in Medical Practice Egilius L.H. Spierings, MD, PhD, Willem K.P. Mutsaerts, MSc Department of Neurology, Brigham and
More informationTreatment of Substance Abuse and Co-occurring Disorders in JRA s Integrated Treatment Model
Treatment of Substance Abuse and Co-occurring Disorders in JRA s Integrated Treatment Model Henry Schmidt III, Ph.D. Cory Redman John Bolla, MA, CDP Washington State Juvenile Rehabilitation Administration
More informationLEVEL III.5 SA: SHORT TERM RESIDENTIAL - Adult (DUAL DIAGNOSIS CAPABLE)
LEVEL III.5 SA: SHT TERM RESIDENTIAL - Adult (DUAL DIAGNOSIS CAPABLE) Definition The following is based on the Adult Criteria of the Patient Placement Criteria for the Treatment of Substance-Related Disorders
More informationUnraveling (some of) The Mystery of Borderline Personality Disorder Have we been barking up the wrong tree?
Unraveling (some of) The Mystery of Borderline Personality Disorder Have we been barking up the wrong tree? Barbara Stanley, Ph.D. Director, Suicide Intervention Center New York State Psychiatric Institute
More informationRecognizing and Treating Depression in Children and Adolescents.
Recognizing and Treating Depression in Children and Adolescents. KAREN KANDO, MD Division of Child and Adolescent Psychiatry Center for Neuroscience and Behavioral Medicine Phoenix Children s Hospital
More informationMedication Management of Depressive Disorders in Children and Adolescents. Satya Tata, M.D. Kansas University Medical Center
Medication Management of Depressive Disorders in Children and Adolescents Satya Tata, M.D. Kansas University Medical Center First Line Medications SSRIs Prozac (Fluoxetine): 5-605 mg Zoloft (Sertraline):
More informationIn 2010, approximately 8 million Americans 18 years and older were dependent on alcohol.
Vivitrol Pilot Study: SEMCA/Treatment Providers Collaborative Efforts with the treatment of Opioid Dependent Clients Hakeem Lumumba, PhD, CAADC SEMCA Scott Schadel, MSW, LMSW, CAADC HEGIRA PROGRAMS, INC.
More informationMajor Depressive Disorder:
Major Depressive Disorder: An Actuarial Commercial Claim Data Analysis July 2013 Prepared by: Milliman, Inc. NY Kate Fitch RN, MEd Kosuke Iwasaki FIAJ, MAAA, MBA This report was commissioned by Takeda
More informationStudy Guide - Borderline Personality Disorder (DSM-IV-TR) 1
Study Guide - Borderline Personality Disorder (DSM-IV-TR) 1 Pervasive pattern of instability of interpersonal relationships, selfimage, and affects, and marked impulsivity that begins by early adulthood
More informationBehavioral Health Covered Services
Behavioral Health Covered Services Inpatient Services - 24-hour services, delivered in a licensed hospital setting, that provide clinical intervention for mental health or substance use diagnoses, or both.
More informationBreaking the cycles of Borderline Personality Disorder
Breaking the cycles of Borderline Personality Disorder Borderline Personality Disorder (BPD) is a complex and difficult to treat condition affecting up to 2 % of the UK s adult population, and 50 % of
More informationDepression in Older Persons
Depression in Older Persons How common is depression in later life? Depression affects more than 6.5 million of the 35 million Americans aged 65 or older. Most people in this stage of life with depression
More informationBorderline Personality Disorder Research Update: Childhood Precursors, Predictors, & Risk Factors
Borderline Personality Disorder Research Update: Childhood Precursors, Predictors, & Risk Factors Stephanie D. Stepp, Ph.D. Associate Professor Department of Psychiatry & Psychology University of Pittsburgh
More informationin young people Management of depression in primary care Key recommendations: 1 Management
Management of depression in young people in primary care Key recommendations: 1 Management A young person with mild or moderate depression should typically be managed within primary care services A strength-based
More informationBarriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness
Barriers to Healthcare Services for People with Mental Disorders Cardiovascular disorders and diabetes in people with severe mental illness Dr. med. J. Cordes LVR- Klinikum Düsseldorf Kliniken der Heinrich-Heine-Universität
More informationPrepared by:jane Healey (Email: janie_healey@yahoo.com) 4 th year undergraduate occupational therapy student, University of Western Sydney
1 There is fair (2b) level evidence that living skills training is effective at improving independence in food preparation, money management, personal possessions, and efficacy, in adults with persistent
More information